R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Life sciences industry predictions 2024: Curavit

December is here; the end of 2023 fast approaches. For those operating in the life sciences sector, it’s all too clear that the time has come for 2024 industry predictions.

Patients

On Pfizer’s initiative to return clinical trial data to pati...

Among the most common reasons for dropping out, patients cite a lack of communication about the trial

R&D

Biofidelity’s ASPYRE: The future is bright for oncology

Genomic technology company Biofidelity has announced the launch of ASPYRE-Lung reagents (RUO) for research use, marking its second product launch this year, with the aim of providing simple

R&D

The Oxford R21 malaria vaccine and the imperative of continu...

Malaria, a disease caused by the plasmodium parasite and transmitted through the bite of infected mosquitoes, has been a long-standing global health challenge.

R&D

How to advance more late-stage neuroscience drugs to regulat...

As a practicing neuropsychiatrist for more than a decade, I witnessed firsthand the profound unmet need in neurological and psychiatric disorders including epilepsy, neurodegenerative disea

Patients

PCR in pharma packaging: A sustainable solution for tomorrow...

Amidst the growing concerns over plastic waste and the evolving landscape of environmental regulations, the pharmaceutical industry, known for its heavy reliance on plastic for various pack